Tenable Holdings 株価情報 (NASDAQ: TENB)

最新ニュース Tenable Holdings (NASDAQ:TENB) 株価情報

Tenable Holdings

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

Tenable Holdings Inc

Macro Economic Events

News

Politics

Economics

General

President Trump Agreed To Immediately Pause The Anticipated Tariffs For A One Month Period With Mexico's President; Says We Will Have Negotiations Headed By Rubio, Bessent, Howard Lutnick, And Mexican Officials, Says Look Forward To Participating In Those Negotiations With President Sheinbaum As We Attempt To Achieve A "Deal" Between Our Two Countries

RBC Capital analyst Brian Abrahams maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $139 to $143.

Price Target

Analyst Ratings

AXSM

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $143

Wells Fargo analyst Jason Haas maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Overweight and lowers the price target from $321 to $313.

Wells Fargo Maintains Overweight on Equifax, Lowers Price Target to $313

WIIM

ELUT

Elutia shares are trading lower after the company announced it secured a $15.6 million direct offering of 5.52 million shares.

The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) will release earnings results for its second quarter, after the <a href="https://www.benzinga.com/quote/CLX/earnings">closing bell on Monday, Feb. 3, 2025.</a>
Analysts expect the Oakland, California-based company to report quarterly earnings at $1.4 per share, down from $2.16 per share in the year-ago period. Clorox projects to report revenue of $1.63 billion for the recent quarter, compared to $1.99 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 28, The Clorox Company said that CFO Kevin Jacobsen will retire on April 1 after almost 30 years at the company.
Clorox shares fell 1.1% to close at $158.68 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Lauren Lieberman maintained an Underweight rating and cut the price target from $139 to $130 on Jan. 17, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Wells Fargo analyst Chris Carey upgraded the stock from Underweight to Equal-Weight and raised the price target from $155 to $157 on Jan. 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>TD Cowen analyst Robert Moskow upgraded the stock from Sell to Hold and raised the price target from $155 to $170 on Nov. 6, 2024. This analyst has an accuracy rate of 67%.</li>
<li>DA Davidson analyst Linda Bolton Weiser maintained a Neutral rating and boosted the price target from $153 to $171 on Nov. 4, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Citigroup analyst Wendy Nicholson maintained a Neutral rating and increased the price target from $165 to $170 on Sept. 6, 2024. This analyst has an accuracy rate of 64%.</li>
</ul>
Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1018" height="556" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03045156/image-1.png" alt="" class="wp-image-762185" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03045156/image-1.png 1018w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03045156/image-1-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03045156/image-1-768x419.png 768w" sizes="(max-width: 1018px) 100vw, 1018px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Markets

Trading Ideas

Clorox Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

On Monday, Invivyd Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rallied on the heels of a new data report <a href="https://www.benzinga.com/topic/covid-19">involving a COVID-19 treatment</a>. 
The company is conducting an ongoing Phase 1/2 trial of VYD2311, a monoclonal antibody (mAb) candidate. A formal estimate of in vivo half-life is not yet available for VYD2311 given the long apparent half-life thus far.
As of Day 65, serum concentrations remain high, potentially substantially increasing the observed half-life of VYD2311 relative to pemivibart, the company&#8217;s&nbsp;monoclonal antibody&nbsp;medication authorized for the&nbsp;pre-exposure prophylaxis&nbsp;(prevention) of&nbsp;COVID‑19.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42920654/whats-going-on-with-covid-19-antibody-developer-invivyd-stock-on-friday" rel="noreferrer noopener">What&#8217;s Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?</a>
Analysis for the IM cohort (the most advanced cohort in time) is tracking generally with the PK profile of adintrevimab, a previous Invivyd mAb with an estimated in vivo half-life of 139 days.
PK analysis of VYD2311 intravenous and subcutaneous cohorts at earlier timepoints, at either similar doses subcutaneously or higher doses intravenously, are similarly and encouragingly tracking close to the estimated curves for adintrevimab thus far.
In vitro neutralization data generated continuously on VYD2311 as part of Invivyd&#8217;s industrial virology efforts demonstrate an average potency improvement for VYD2311 of approximately 17-fold compared to pemivibart.
The combined safety, pharmacokinetics (PK), and virology data for VYD2311, along with findings from Invivyd&#8217;s CANOPY Phase 3 trial and previous monoclonal antibody (mAb) studies, suggest that VYD2311 could offer strong and long-lasting protection against COVID-19.
A single dose may provide high protective antibody levels for six months to a year or longer.
The company also reported preliminary fourth quarter 2024 Pemgarda (pemivibart) net product revenue of $13.8 million. That&#8217;s 48% growth over Q3 2024 net product revenue of $9.3 million.
The company&#8217;s preliminary ending 2024 cash and cash <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43429956/invivyd-announces-preliminary-fourth-quarter-2024-financial-results-strong-revenue-growth-and-reit" rel="noreferrer noopener">equivalents of $69.3 million</a>.
Price Action: Invivyd stock is up 72.8% at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43432128/owens-minor-stock-dips-on-mixed-q4-preliminary-results-310-million-apria-goodwill-charge-details" target="_blank" rel="noreferrer noopener">Owens &amp; Minor Stock Dips On Mixed Q4 Preliminary Results &amp; $310 Million Apria Goodwill Charge: Details</a></li>
</ul>

Biotech

Health Care

IVVD

Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps

RBC Capital analyst Scott Heleniak maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Sector Perform and raises the price target from $390 to $400.

RBC Capital Maintains Sector Perform on Aon, Raises Price Target to $400

Splash Beverage Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBEV#NYSE">SBEV</a>), an innovator in the beverage industry, proudly announces another 2024 retail expansion win. Total Wine &amp; More, America's Wine Superstore and the country's largest independent retailer of fine wine, has authorized Pulpoloco Sangria across multiple states. This authorization includes Pulpoloco' Smooth Red and Crisp White Sangria varietals and spans over 115 stores in Arizona, California, Colorado, Florida, Illinois, Nevada, Texas, and Virginia.
Known for its exceptional selection of fine wines, spirits, and variety, Total Wine &amp; More is a trusted destination for consumers seeking new and exciting beverage options. The addition of Pulpoloco Sangria to their shelves underscores the growing popularity and appeal of this innovative sangria brand, which combines authentic Spanish flavors with convenience and sustainability.

SBEV

Splash Beverage Group Expands Pulpoloco Sangria Distribution With Total Wine & More; Authorization Includes Pulpoloco' Smooth Red And Crisp White Sangria Varietals And Spans Over 115 Stores In Arizona, California, Colorado, Florida, Illinois, Nevada, Texas, And Virginia

U.S. stocks traded lower this morning, with the Nasdaq Composite dipping 1.5% on Monday.
Following the market opening Monday, the Dow traded down 0.63% to 44,262.92 while the NASDAQ dipped 1.50% to 19,334.02. The S&amp;P 500 also fell, dropping, 1.13% to 5,972.20.
Check This Out: <a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a>
Leading and Lagging Sectors Consumer staples shares surged by 0.4% on Monday.
In trading on Monday, information technology shares fell by 2%.
Top Headline
Tyson Foods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) posted better-than-expected first-quarter FY25 earnings result.
The company reported first-quarter FY25 sales growth of 2.3% year-on-year to $13.62 billion, beating the analyst consensus estimate of $13.44 billion.
Adjusted EBITDA for the quarter increased 29.2% to $961 million. Adjusted EPS of $1.14 beat the consensus estimate of $0.88.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 129% to $0.6377 after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>Shares of MDJM Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UOKA#NASDAQ">UOKA</a>)got a boost, surging 92% to $0.2490.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares were also up, gaining 78% to $18.82 after the company&#8217;s inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 55% to $0.1206.</li>
<li>Shares of Heramba Electric plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) were down 51% to $0.4324.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) was down, falling 46% to $0.2292. Tonix Pharmaceuticals announced a 1-for-100 reverse stock split, effective Feb. 5.</li>
</ul>
Commodities In commodity news, oil traded down 0.4% to $72.26 while gold traded up 0.9% at $2,861.10.
Silver traded up 0.4% to $32.390 on Monday, while copper rose 0.1% to $4.2815.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.5%, Germany's DAX 40 dipped 2.1% and France's CAC 40 declined 1.9%. Spain's IBEX 35 Index fell 2.1%, while London's FTSE 100 fell 1.5%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 2.66%, Hong Kong's Hang Seng Index fell 0.04% and India's BSE Sensex falling 0.41%.
Economics
<ul>
<li>U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.</li>
<li>The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.</li>
<li>The S&amp;P Global manufacturing PMI rose to 51.2 in January, versus a preliminary reading of 50.1 and compared to 49.4 in December.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/02/43432854/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PepsiCo Stock Ahead Of Q4 Earnings</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

GHRS

HCWB

PITA

TNXP

UOKA

S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and raises the price target from $195 to $210.

ABBV

Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $210

Wells Fargo analyst Elyse Greenspan maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Overweight and raises the price target from $410 to $445.

Wells Fargo Maintains Overweight on Aon, Raises Price Target to $445

RBC Capital analyst Kenneth Lee reiterates Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) with a Outperform and maintains $625 price target.

Reiteration

RBC Capital Reiterates Outperform on Ameriprise Finl, Maintains $625 Price Target

Market Summary

SPDR Dow Jones Industrial Average ETF Trust

Benzinga Market Summary: S&P Falls On Tariff Announcement But Rebounds After Mexico Announces One Month Pause On Tariffs And Troop Deployment To Border, Bitcoin Slides

<a href="https://www.youtube.com/watch?v=_8LeV244VZo" title="https://www.youtube.com/watch?v=_8LeV244VZo">https://www.youtube.com/watch?v=_8LeV244VZo</a>

Global

Mexican President Sheinbaum Says Conversation With Trump Was Long, Covered Subjects Of Mutual Interest; Says She Proposed The Tariffs Pause To Trump; Asked For U.S. To Help Stem Traffic Of Guns Coming From Us, Trump Was In Agreement; Says Trump Insisted On Addressing Trade Deficit With Mexico, But She Pushed Back On That; Says I Am Sure That In This One Month We Can Achieve Results; Deal Will Also Help Mexico Boost Border Security

Piper Sandler analyst Korinne Wolfmeyer maintains Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) with a Overweight and lowers the price target from $128 to $126.

Piper Sandler Maintains Overweight on Church & Dwight Co, Lowers Price Target to $126

Wells Fargo analyst Elyse Greenspan maintains Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Overweight and lowers the price target from $130 to $126.

Wells Fargo Maintains Overweight on Hartford Finl Servs Gr, Lowers Price Target to $126

Major indexes are lower following US tariffs on Canada, Mexico and China. Mexican President Sheinbaum has reportedly said tariffs on Mexico will be paused one month and has announced troop deployment on the border. The S&P rebounded from lows following the announcement.

PROC

Procaps Group shares are trading lower after the company announced it received a Nasdaq delisting notice.

RBC Capital analyst Kenneth Lee maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Outperform and lowers the price target from $90 to $85.

VOYA

RBC Capital Maintains Outperform on Voya Financial, Lowers Price Target to $85

Tonix Pharmaceuticals shares are trading lower after the company announced a 1-for-100 reverse stock split.

Rapid7, Tenable cut to Hold at Stifel on low priority of vulnerability management

Scotiabank analyst Patrick Colville raised the firm's price target on Tenable (TENB) to $45 from $44 and keeps a Sector Perform rating on the share...

Tenable price target raised to $45 from $44 at Scotiabank

Analysts, along with Eron Howard, COO at Novacoast and Jeremy Wittkop, Principal Enterprise Architect at Proofpoint, discuss quarterly industry and...

DA Davidson enterprise security analysts hold analyst/industry conference call

Tenable to acquire Vulcan Cyber for $147M in cash and $3M of restricted stock units

Tenable (TENB) announced that it has signed a definitive agreement to acquire Vulcan Cyber. Vulcan Cyber's capabilities will augment Tenable's indu...

Tenable plans to acquire Vulcan Cyber for $147M in cash, $3M in RSUs

Analyst Shrenik Kothari from Robert W. Baird maintained a Buy rating on Tenable Holdings (TENB – Research Report) and keeping the price target at $...

Tenable Holdings' Strategic Acquisitions Bolster Exposure Management and Cloud Security Capabilities

TD Cowen analyst Shaul Eyal reiterated a Buy rating on Tenable Holdings (TENB – Research Report) today and set a price target of $55.00. The compan...

Tenable Holdings (TENB) Receives a Rating Update from a Top Analyst

Tenable Holdings ( ($TENB) ) has issued an update. On January 29, 2025, Tenable Holdings announced a definitive agreement to acquire Vulcan Cyber L...

Tenable Holdings Acquires Vulcan Cyber for $150 Million

In a report released today, Patrick Colville from Scotiabank reiterated a Hold rating on Tenable Holdings (TENB – Research Report), with a price ta...

Comments

Tenable Holdings

ニュース

最新ニュース Tenable Holdings (NASDAQ:TENB) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル